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ABSTRACT
Leishmaniasis is one of the six major tropical diseases targeted by the World Health Organization. It is a life-threatening disease 
of medical, social and economic importance in endemic areas. No vaccine is yet available for human use, and chemotherapy 
presents several problems. Pentavalent antimonials have been the drugs of choice to treat the disease for more than six decades; 
however, they exhibit high toxicity and are not indicated for children, for pregnant or breastfeeding women or for chronically ill 
patients. Amphotericin B (AmpB) is a second-line drug, and although it has been increasingly used to treat visceral leishmaniasis 
(VL), its clinical use has been hampered due to its high toxicity. This review focuses on the development and in vivo usage of 
new delivery systems for AmpB that aim to decrease its toxicity without altering its therapeutic efﬁ cacy. These new formulations, 
when adjusted with regard to their production costs, may be considered new drug delivery systems that promise to improve the 
treatment of leishmaniasis, by reducing the side effects and the number of doses while permitting a satisfactory cost-beneﬁ t ratio.
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INTRODUCTION
Leishmaniasis presents a broad spectrum of clinical 
manifestations and is caused by different species of protozoa 
belonging to the genus Leishmania(1). The disease displays high 
morbidity and mortality throughout the world, with approximately 
350 million people in 98 countries at risk of contracting the 
infection(2). Approximately 700,000 to 1.2 million cases of 
tegumentary leishmaniasis (TL) and 200,000 to 400,000 cases 
of visceral leishmaniasis (VL) are registered annually(3). Visceral 
leishmaniasis represents an important disease worldwide, leading 
to nearly 50,000 deaths each year(4) (5) (6). Because of its remarkable 
impact on global public health, leishmaniasis is considered 
one of the six major tropical diseases by the World Health 
Organization, and it has gained greater importance in HIV-
infected individuals as an opportunistic infection in areas where 
both infections are endemic(7). Leishmaniasis has thus become 
the third most common parasitic disease after toxoplasmosis 
and cryptosporidiosis(8).
In Brazil, VL is caused by Leishmania (Leishmania) infantum 
chagasi species(9). Dogs are the main domestic reservoirs of 
the parasites and play a central role in the transmission cycle 
between humans and sandﬂ ies(10). The disease is characterized 
by clinical manifestations based on irregular fever, weight loss, 
pallor, splenomegaly, and pancytopenia, and it carries a high 
risk of mortality in the absence of treatment(11). Nevertheless, 
the outcomes of infection can vary from asymptomatic and/
or subclinical disease to an acute symptomatic form. The 
asymptomatic disease is characterized by subjects infected by 
the parasites but with no apparent impact on their health, whereas 
the acute disease is characterized by clinical manifestations 
such as lymphadenopathy, fever, diarrhea, malaise, coughing, 
mild hepatomegaly and/or splenomegaly, as well as a positive 
laboratory diagnosis(12).
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Currently, there is no gold-standard test for the diagnosis 
of leishmaniasis, and a combination of different methods 
is frequently needed to obtain more precise results. The 
serological diagnosis of VL has been based on the detection 
of antileishmanial antibodies in serum samples of patients. 
However, these tests have problems related to their sensitivity 
and/or speciﬁ city(13). The parasitological diagnosis is based on 
the demonstration of amastigote forms in collected specimens; 
however, these tests require invasive procedures for sample 
collection, which limit their use in large-scale epidemiological 
studies(14). The detection of Leishmania spp. Deoxyribonucleic 
acid (DNA) by the polymerase chain reaction technique is also 
performed, but it is costly(15).
Historically, chemotherapy to treat leishmaniasis has 
been based on the parenteral administration of pentavalent 
antimonials(16). These drugs are effective, presenting an efﬁ cacy 
of approximately 90%(17), but there has been growing evidence 
of variable efﬁ cacy that depends on the species, geographic 
region, presence of resistant strains, and therapeutic schemes 
employed(18) (19) (20). Moreover, certain factors, such as the 
need for parenteral administration for up to 30 days, the high 
frequency of side effects such as myalgia, arthralgia, anorexia, 
fever and urticaria, and signiﬁ cant toxicity to the liver, kidneys 
and spleen of the patient, have contributed to the limited use 
of these drugs in clinical practice(21) (22). Pentamidine, another 
antileishmanial drug, is also unsuitable as a ﬁ rst-line treatment 
due to its toxicity. Clinical results using oral miltefosine have 
been encouraging; however, this drug has been linked to 
teratogenicity and should not be prescribed to pregnant women 
or to those of childbearing age(23).
Drug delivery systems have received considerable attention 
in the ﬁ eld of drug development. Pharmaceutical technology 
has been used to control pharmacokinetic properties, such as 
absorption, distribution, metabolism, and excretion and to improve 
the efﬁ cacy and/or reduce the toxicity of drugs(24). This review 
examines the development and deployment of technologies to 
improve the delivery of drugs for treating leishmaniasis. It focuses 
on recent improvements that have led to reductions in the toxicity of 
amphotericin B (AmpB) and to improvements in the effectiveness 
of AmpB in Leishmania spp. infection models.
AMPHOTERICIN B AND ITS DELIVERY SYSTEMS 
FOR THE TREATMENT OF LEISHMANIASIS
Drug discovery is typically a long and very expensive process, 
requiring an average of 10 to 20 years and an investment of more 
than $1.0 billion before a new compound with activity against 
a speciﬁ c target is identiﬁ ed, characterized, and developed for 
clinical applications(25) (26). In the case of leishmaniasis, there 
are few new antileishmanial drugs in the pipeline, and drug 
resistance is increasing. Over the past few decades, AmpB 
(Figure 1) has been used with increasing frequency to treat 
leishmaniasis. It has been employed to treat systemic fungal 
infections, and its mechanism of action is related to its binding 
to the membrane sterols of parasites. Because Leishmania spp. 
membranes also contain ergosterol, the drug impairs the cell 
permeability of these parasites, leading to the loss of cations, 
such as K+ and causing cell death(27). Moreover, AmpB shows 
effective antileishmanial activity against different Leishmania 
spp. species that have clinical relevance in the Americas, such 
as L. infantum, L. braziliensis and L. amazonensis(28). However, 
the clinical use of AmpB has been limited due to its high 
toxicity, which can cause such clinical symptoms in patients as 
nephrotoxicity, cardiac alterations, hemolysis and liver damage, 
as well as nausea and fever(29) (30).
To reduce the toxicity of AmpB, lipid-based formulations 
have been developed(31). A liposomal formulation (AmBisome®), 
an AmpB colloidal dispersion (Amphocil®), and an AmpB-
lipid complex (Abelcet®) have been used for the treatment of 
leishmaniasis(32) (Figure 2). The World Health Organization 
has recommended the use of liposomal AmpB based on its 
high levels of efficacy and safety(2). The development of 
these formulations has diminished drug toxicity during the 
treatment of leishmaniasis(33). In general, these products are less 
nephrotoxic than free AmpB, as they are taken up selectively 
by macrophages. Additionally, adverse effects, including 
mild urticarial rash and renal impairment, were resolved after 
therapy(34). The main factor limiting the widespread use of 
lipid-AmpB formulations is their high cost. Therefore, the 
search continues for a low-cost formulation that can be used to 
effectively treat leishmaniasis.
Typically, delivery using nano- or microstructured systems 
can result in a higher concentrations and slower release of drugs 
in several mammalian body organs, including the spleen, liver, 
and kidneys(35) (36) (37) (38) (39). Such delivery systems for AmpB have 
been examined; Yang et al.(40) formulated polymeric micelles 
prepared from a series of poly(ethylene glycol)-poly(lactide) 
(PLA) co-polymers with various polylactide chain lengths 
for AmpB. Shao et al.(41) designed polymeric micelles using a 
formulation of 1,2-distearoyl-glycerol-3-phosphoethanolamine-
N-[methoxy(polyethylene glycol)-2000] (PE-PEG)-based 
micelles loaded with AmpB, and they evaluated the presence 
and concentration of this drug in the brains of Sprague-Dawley 
rats. The authors showed that this formulation was effective 
in penetrating the blood-brain barrier of the animals, and 
AmpB was found to be concentrated in the brain. Carvalho 
et al.(42) developed a system containing free desoxycholate 
AmpB encapsulated in poly(lactic-co-glycolic acid) (PLGA) 
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FIGURE 1 - Chemical structure of amphotericin B.
  237
Rev Soc Bras Med Trop 48(3):235-242, May-Jun, 2015
and dimercaptosuccinic acid (DMSA), yielding PLGA-DMSA 
nanoparticles. These products were evaluated in the treatment 
of experimental cutaneous leishmaniasis in C57BL/6 mice to 
determine whether the nano-drug delivery system would favor 
a reduction in the dose frequency required to achieve the same 
therapeutic level as free AmpB, thereby extending the dosing 
interval. The authors evaluated paw diameter measurements 
and the parasite loads of the animals by using a limiting dilution 
technique, and they found that the nano-AmpB delivery system 
was more effective than free AmpB therapy, allowing a reduction 
in the dose frequency required to obtain the same therapeutic 
level. The authors concluded that this system could favor a longer 
interval between doses, as expected with the development of a 
new nano-drug delivery system, and that it might be useful in 
the treatment of different pathologies, including leishmaniasis.
Silva et al.(43) developed an oil-in-water microemulsion 
system (MES) to improve the solubility of AmpB. In their study, 
different nonionic surfactants, such as Tween® and Span®, 
were tested for their solubilization capacity in combination 
with different oils. The AmpB-loaded MES was able to improve 
the solubility of AmpB up to 1,000-fold, and a portion of the 
AmpB in the system was aggregated in a drug reservoir format. 
Additionally, cytotoxicity studies revealed limited toxicity 
to macrophages, suggesting that this formulation could be a 
suitable carrier for AmpB that would also reduce its in vivo 
toxicity. Unfortunately, such examples frequently require 
the use of organic solvents or heating, which are undesirable steps 
because they can affect the integrity of macrolide substances(44) (45). 
Recently, Gupta et al.(46) developed a formulation based on 
the incorporation of AmpB into lipo-polymerosome (AmB-
L-Psome®), and they performed in vitro (with intracellular 
amastigotes) and in vivo (with L. donovani-infected hamsters) 
studies comparing this delivery system with commercial 
Ambisome® and Fungizone®. The authors showed that 
AmB-L-Psome® displayed lower toxicity than Fungizone® 
and Ambisome® along with higher antileishmanial activity. 
Their results were based on the up-regulation of Th1 cytokines 
[tumor necrosis factor alpha (TNF-α), interleukin-12 (IL-12) and 
interferon gamma (IFN-γ)] and inducible nitric oxide synthase 
and the down-regulation of Th2 cytokines [tumor necrosis 
factor beta (TNF-β), IL-10 and IL-4], which were evaluated 
by quantitative messenger ribonucleic acid (mRNA) detection 
in infected animals using real-time reverse-transcriptase-
polymerase chain reaction (RT-PCR). The authors concluded 
that their newly developed AmB-L-Psome® system could be a 
viable alternative to the less stable and more toxic commercial 
formulations in current use and that it could be developed as a 
highly efﬁ cacious drug delivery system.
In addition, Kumar et al.(47) developed carboxy-terminated 
poly(D,L-lactide–co–glycolide)–block–poly(ethylene glycol) 
(PLGA-PEG)-encapsulated AmpB nanoparticles to increase the 
solubility of AmpB and to target the macrophages of infected 
tissues during L. donovani infection. Their study showed that the 
cytotoxicity of extracellular promastigotes when using PLGA-
PEG-encapsulated AmpB was signiﬁ cantly lower than that 
with free AmpB and that the inhibition of amastigote infection 
in the spleens of the animals was signiﬁ cantly higher than 
with free AmpB. The authors concluded that the PLGA-PEG-
encapsulated AmpB nanoparticles were more therapeutically 
effective than free AmpB in both in vitro and in vivo studies of 
L. donovani infection.
OPTIMIZED NANOPARTICLE DELIVERY 
SYSTEMS FOR AMPB BASED ON CHITOSAN 
AND CHONDROITIN SULFATE MOLECULES
Because of the above-mentioned problems, the development 
of new delivery systems for the treatment of leishmaniasis 
is considered important. Polyelectrolyte complexes (PECs) 
are formed by interactions between macromolecules bearing 
oppositely charged groups. The encapsulation of a drug during 
A B C
FIGURE 2 - Lipid-based formulations of AmpB. The structural characterization of three lipid-based formulations of amphotericin B 
are shown A: AmBisome®, B: AmphocilH® and C: Abelcet®.
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the formation of PECs has shown great promise for use as a 
drug delivery system(48). Recently, PECs prepared from natural 
macromolecules, such as chitosan (Cs) and heparin complexes, 
have been formulated for use as vaccine adjuvants and have 
attracted attention for the development of new drug delivery 
systems(49). Studies have also investigated drug delivery systems 
based on Cs and chondroitin sulfate (ChS) molecules. Such 
reports include Ganza-Gonzales et al.(50), Sui et al.(51), and Huang 
et al.(52), which described the use of Cs-Chs-based microcapsules 
for the controlled release of heparin, metoclopramide and 
5-ﬂ uorouracil, respectively. The main advantage of this method 
is that it allows the production of delivery systems without the 
need for organic solvents in their formulations(30).
Chitosan [b-(1,4)-2-amino-2-deoxy-D-glucan], which is 
prepared from chitin by deacetylation, has many interesting 
properties, including biocompatibility, biodegradability, 
mucoadhesivity, and bioactivity(53). Chitosan has an intrinsic 
pKa near 6.5, with a maximum net positive charge of one 
per residue(54). Chondroitin sulfates are glycosaminoglycans 
that are present in the extracellular matrix of cartilage, and 
they are used for the treatment of osteoarthritis and for their 
anti-inﬂ ammatory activity(55). They are also components of 
the dermal layer of an Food and Drug Administration (FDA)-
approved skin substitute(56) and are commonly used to enhance 
re-epithelialization without causing scarring(57) (58). Moreover, 
ChS molecules are similar to their endogenous homologs, which 
can be degraded by the colonic microﬂ ora(59).
Recently, an optimized nanoparticle system, based on PECs 
using natural polymers (Cs and ChS) and incorporating AmpB, 
was developed (Figure 3), and its antileishmanial activity was 
evaluated against extracellular promastigotes and intracellular 
amastigotes of L. infantum and L. amazonensis(30). In this study, 
Cs nanoparticles (NQ), Cs-ChS nanoparticles (NQC), and 
Cs-ChS-AmpB nanoparticles (NQC-AmpB) all showed effective 
in vitro antileishmanial activity. In addition, a synergistic 
interaction between the Cs and ChS molecules was observed. 
Interestingly, the toxicity of the NQC-AmpB system was 
approximately 10 times less than that of free AmpB. In addition, 
the selectivity index (SI), an indicator of the selectivity of drugs 
tested in in vivo models(60), was increased by 10-fold when AmpB 
was added to the proposed nanodelivery system. Because the 
nanoparticle formulations did not cause any hemolysis of human 
red blood cells(31) (Table 1), the study suggested that the NQC-
AmpB nanoparticles could be used as an AmpB delivery system to 
be evaluated in in vivo models against Leishmania spp. infections.
Another study was performed using NQC-AmpB 
nanoparticles to evaluate the ex vivo biodistribution proﬁ le of 
this delivery system in murine models. The compounds were 
radiolabeled with 99mTecnecium, and high uptake of NQC-
AmpB nanoparticles in the livers and spleens of naive BALB/c 
mice was observed by scintigraphic images up to 24 hours after 
administration(61). These ﬁ ndings corroborated other studies 
evaluating nanostructured systems, such as polymeric micelles(62) 
and gold nanoparticles(63), in which higher concentrations of the 
products were also found in these organs. Because the spleen is 
considered a systemic organ for the transit and homing of T cells 
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FIGURE 3 - Preparation of NQC-AmpB nanoparticles. The 
diagram shows models of the engineered nanoparticles, namely 
(A) NQ, (B) NQC, and (C) NQC-AmpB nanoparticles. The NQ 
nanoparticles were formulated by the PEC technique using Cs 
and TPP. The NQC nanoparticles were formulated by PEC 
using Cs, ChS and TPP, and the NQC-AmpB nanoparticles 
were formulated by PEC using Cs, ChS, and TPP, and AmpB. 
NQ: chitosan nanoparticle; TPP: sodium triphosphate; NQC-AmpB: 
chitosan-chondroitin sulfate nanoparticle-amphotericin B; AmpB: 
amphotericin B; NQC: chitosan-chondroitin sulfate nanoparticle; 
PEC: polyelectrolyte complexation; Cs: chitosan; ChS: chondroitin sulfate.
in mammal hosts, and because it is an important site of infection 
for Leishmania spp. parasites(64), one may speculate that the 
greater presence of the NQC-AmpB nanoparticles in the spleen 
might be adequate for the treatment of leishmaniasis. Remarkably, 
ChS has been detected in many tissues and host cells(65), and 
it has been reported to biologically interact with important 
molecules and to regulate their functions. It was reported that 
the Th1-promoting and Th2-inhibitory activities of ChS were 
associated with its binding to such adhesion molecules as 
L- and P-selectins, clustter of differentiation 4 (CD4)  molecules, 
and chemokines(66). The immune-stimulatory activity of ChS 
Chávez-Fumagalli MA et al. - Amphotericin B delivery systems to treat leishmaniasis
  239
may be due to its binding to L-selectins expressed on the 
T cell surface(67). In this sense, the cellular response induced by 
Cs in an infected spleen might help the host immune system to 
eliminate intracellular amastigotes. In addition, a toxicological 
analysis was performed on the livers of animals that received 
NQC-AmpB nanoparticles. A signiﬁ cant increase in hepatocyte-
associated serum enzymes was observed in animals treated with 
free AmpB, resulting in signiﬁ cant elevation of the levels of 
gamma-glutamyltransferase (GGT), aspartate aminotransferase 
(AST), and alanine aminotransferase (ALT) enzymes. Meanwhile, 
animals that received NQC-AmpB did not show any enzymatic 
alterations(61). These results demonstrated a decrease in hepatic 
toxicity when AmpB was administered using the NQC system(61).
Nephrotoxicity is perhaps the most-described adverse event 
associated with AmpB(68). The pathophysiology and pharmacology 
of this activity are well-documented, and the proposed 
mechanism has been described as multifactorial(69) (70). 
Early studies proposed renal tubular toxicity and afferent 
arteriolar vasoconstriction as possible physiological factors 
related to AmpB-induced nephrotoxicity, but the underlying 
mechanistic explanation for injury remains poorly understood(71). 
Inflammation plays a central role in the pathogenesis of 
drug-induced kidney injury. Inﬂ ammation is mediated by the 
expression of cytokines upon the activation of Toll-like receptors 
(TLRs) located on the renal parenchymal and tubule-interstitial 
cells. The net inﬂ ammatory response entails a coordinated 
balance between pro-inflammatory and anti-inflammatory 
mediators; a relative exuberance of the former predisposes 
tissue to injury. The pro-inﬂ ammatory nature of AmpB has 
been characterized, and it is believed to be mediated by the 
engagement of TLR2 and TLR4, which results in the activation 
of NF-kB and the production of cytokines(72). In this context, 
Chai et al.(73) demonstrated that, among patients receiving 
AmpB therapy, temporal trends in pro-inﬂ ammatory cytokine 
levels had greater clinical signiﬁ cance than their absolute levels. 
As new light is shed on the mechanisms of AmpB-induced 
nephrotoxicity via the signaling pathways that mediate tissue 
inﬂ ammation, an important goal is to develop novel management 
and/or delivery strategies that minimize the adverse effects of 
this time-tested antifungal agent. One such measure might be 
the use of N-acetylcysteine, which, in accord with its utility in 
contrast-induced nephropathy, also has anti-inﬂ ammatory and 
therapeutic properties(74). In addition, delivery systems based on 
ChS molecules may be useful, as these molecules also possess 
anti-inﬂ ammatory activity and may reduce the nephrotoxicity 
caused by free AmpB.
Ribeiro et al.(61) showed that the levels of urea in blood, as well 
as serum creatinine levels, were signiﬁ cantly higher in animals 
treated with free AmpB than in those treated with NQC-AmpB 
nanoparticles. The alterations detected in the kidneys of AmpB-
treated animals by microscopic observation were in accord with 
those described in previous studies(75). In contrast, animals treated 
with NQC-AmpB showed no pathological alterations in this 
tissue. It may therefore be concluded that the decrease in AmpB 
toxicity in the NQC-AmpB preparation relative to free AmpB 
might have occurred because the nanoparticle-encapsulated 
AmpB did not interact with the cell membranes within the kidney 
tubules, thereby minimizing nephrotoxicity(61).
Finally, the efficacy of NQC-AmpB nanoparticles for 
treating chronically L. amazonensis-infected BALB/c mice 
was evaluated in comparison to the free drug. Although both 
NQC-AmpB and free AmpB treatments were able to induce a 
signiﬁ cant reduction in the parasite load in the infected animals 
(Figure 4), the NQC-AmpB system was less toxic than free 
AmpB. The authors concluded that NQC-AmpB nanoparticles 
may be used as an alternative AmpB delivery system that 
maintains the high activity of this drug against Leishmania spp. but 
signiﬁ cantly reduces its toxicity relative to that of the free drug(61).
TABLE 1 - Antileishmanial activity, cytotoxicity, hemolytic activity and selectivity index of Cs, ChS, NQ, NQC, NQC-AmpB 
nanoparticles and free AmpB. 
       Inhibitory activity (μg/mL)
                     Selectivity index
 L. amazonensis L. infantum Murine macrophages Red blood cells  (SI: CC50/IC50)d
Compounds and formulations (IC50)a (IC50) (CC50)b (RBC50)c L. amazonensis L. infantum
Cs 73.00 ± 5.70 67.10 ± 4.55 1,559.00 ± 10.00 432.00 ± 21.00 21.36 23.30
ChS 65.99 ± 5.60 71.00 ± 10.00 1,349.00 ± 142.00 697.00 ± 106.00 20.43 19.00
NQ 51.86 ± 1.74 45.64 ± 5.51 831.19 ± 13.22 237.83 ± 25.50 16.03 18.21
NQC 43.90 ± 1.49 38.47 ± 1.42 1,189.27 ± 66.47 316.49 ± 4.17 27.10 30.91
NQC-AmpB 0.09 ± 0.01  0.11 ± 0.07 8.92 ± 0.18 239.65 ± 32.46 94.93 83.39
AmpB 0.10 ± 0.02 0.09 ± 0.01 0.78 ± 0.21 12.21 ± 2.70 7.80 8.67
aIC50: concentration needed to inhibit 50% of Leishmania spp. viability. 
bCC50: concentration needed to inhibit 50% of macrophage viability. 
cRBC50: 
concentration needed to lyse 50% of O+ human red blood cells. dSI: selectivity index, calculated as the ratio between the CC50 and IC50 levels. Cs: chitosan; 
ChS: chondroitin; NQ: Cs nanoparticle; NQC: Cs-ChS nanoparticle; AmpB: amphotericin B; NQC-AmpB: AmpB-Cs-ChS nanoparticle; L.: Leishmania. The 
results are expressed as means ± standard deviations. The results are expressed as means ± standard deviations.
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CONCLUSIONS
New drug identification, development and registration 
represent expensive and time-consuming tasks that typically 
cause pharmaceutical companies to neglect new strategies for 
the treatment of leishmaniasis. Although some drugs that treat 
this disease are available, their high toxicity to patients can 
cause interruption of the therapeutic regimen. Therefore, it is 
desirable to develop new delivery systems that maintain the 
antileishmanial activity of these drugs but reduce their toxicity. 
There are some delivery systems currently under development 
and/or in clinical trials, but they are generally costly. In contrast, The authors declare that there is no conﬂ ict of interest.
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FIGURE 4 - Protective efﬁ cacy of the chitosan-chondroitin sulfate nanoparticle-amphotericin B (NQC-AmpB) nanoparticles against 
Leishmania amazonensis infection. BALB/c mice were subcutaneously infected with 5 × 106 stationary-phase promastigotes of 
L. amazonensis (IFLA/BR/1967/PH-8), and the course of infection was monitored for 115 days. When the animals developed ulcerated 
lesions presenting an average diameter of 2 to 3 mm, they were divided into groups according to lesion size. They were then treated for 10 
days with intravenous injections according to one of the following regimens: I) Control group, in which mice received 100μL of saline; II) 
amphotericin B (AmpB) group, in which mice received 100μL of 1mg/kg body weight of AmpB; III) chitosan nanoparticle (NQ) group, 
in which mice received 100μL of chitosan (Cs) nanoparticles, at equivalent amounts of Cs relative to the NQC-AmpB nanoparticles; 
IV) chitosan-chondroitin sulfate nanoparticle (NQC) group, in which mice received 100μL of empty Cs- chondroitin sulfate (ChS) 
nanoparticles at equal amounts of Cs-ChS relative to the NQC-AmpB nanoparticles; -NQC-AmpB group, in which mice received 100μL 
of AmpB-loaded-Cs-ChS nanoparticles at the dose of 1mg/kg body weight of AmpB. The infected mice were observed for a 30-day period 
after the end of treatment, when the parasite burden in the infected footpads (A), spleen (B), liver (C), and draining lymph nodes (D) was 
evaluated by a limiting-dilution technique. Means ± standard deviations (SDs) of the groups are shown. Data are representative of three 
independent experiments, which yielded similar results. *Indicates a signiﬁ cant difference compared to the saline group.
A
B
C
D
nanoparticles comprised of Cs and ChS molecules could, at 
least in part, solve this problem; as such nanoparticles consist 
of two known and commercially available products. While 
there is presently no estimated value for such nanoparticles, 
there is a real possibility that these formulations will have 
a lower cost than other available nano- and microstructured 
formulations.
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